Two drugmakers looking to recover from financial and legal challenges related to the US opioid epidemic are considering a merger that could be worth up to $7 billion, per a report from Bloomberg on Wednesday.
privacy policy | terms of use | contact us | advertise | pharma blogs | facebook | twitter
Copyright © 2025,